Astellas Researcher And U.S. Team Find Drug Target For Schizophrenia
This article was originally published in PharmAsia News
Executive Summary
Chief Researcher Mitsuyuki Matsumoto of Tokyo-based Astellas Pharma and a research team from the U.S. National Institutes of Mental Health found a protein that leads to the onset of schizophrenia symptoms including loss of memory and movement disorder. The protein SERB2 was discovered through pharmaceutical research on human and animal genomes. Recent testing on mice found that a genetically modified mouse with surplus amounts of SREB2 was found to develop a lighter weight brain, slower movement and lower information processing ability. NIMH team analyzed DNA samples of schizophrenia patients and further confirmed the role of SREB2 as the disease susceptibility gene. (Click here for more - Japanese language
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.